Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EPS (Weighted Average and Diluted) (2019 - 2025)

aTYR PHARMA's EPS (Weighted Average and Diluted) history spans 7 years, with the latest figure at -$0.14 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 17.65% year-over-year to -$0.14; the TTM value through Dec 2025 reached -$0.79, up 8.14%, while the annual FY2025 figure was -$0.8, 6.98% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.14 in Q4 2025 per ATYR's latest filing, up from -$0.26 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.14 in Q4 2025 to a low of -$0.64 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.3, with a median of -$0.24 recorded in 2024.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 61.06% in 2021 against a maximum downside of 304.0% in 2021.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.21 in 2021, then dropped by 23.81% to -$0.26 in 2022, then rose by 3.85% to -$0.25 in 2023, then soared by 32.0% to -$0.17 in 2024, then increased by 17.65% to -$0.14 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's EPS (Weighted Average and Diluted) are -$0.14 (Q4 2025), -$0.26 (Q3 2025), and -$0.22 (Q2 2025).